Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precise intervention strategies for chemotherapy-related bone marrow suppression bleeding in hematologic malignancies
ChiCTR2600118285Phase 4Recruiting
- Sponsor
- Xuancheng People's Hospital
- Start
- Feb 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of eltrombopag and coagulation factor VIIa in Thrombocytopenia, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 3 more (4 arms), sponsored by Xuancheng People's Hospital. Primary endpoints: platelet count, platelet count recovery time without platelet transfusion and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
eltrombopagcoagulation factor VIIa
03
Conditions
Thrombocytopeniaacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on ChiCTR2600118285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118285.